Ausgabe 1/2023
Inhalt (21 Artikel)
Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Keiichi Kikuchi, Kenichiro Akaike, Shiho Takeda, Masayuki Takeda
The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux
Defei Qi, Yuanyuan Dou, Wenke Zhang, Mengqing Wang, Yingying Li, Mingzhu Zhang, Jia Qin, Jinlan Cao, Dong Fang, Jing Ma, Wei Yang, Songqiang Xie, Hua Sun
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors
Shubham Pant, Tomislav Dragovich, Christopher Lieu, Antonio Jimeno, Madappa Kundranda, David Menter, Eskouhie Tchaparian, Yuchih C. Chen, Scott Kopetz
Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence
Yusuke Shima, Yuki Sato, Takeshi Morimoto, Shigeo Hara, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Hiroshi Hamakawa, Yutaka Takahashi, Keisuke Tomii
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)
Kun Qian, Qi-Rui Chen, Ming He, Zi-Tong Wang, Yu Liu, Hua-Gang Liang, Zhi-Yong Su, Yu-Shang Cui, Li-Jun Liu, Yi Zhang
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors
Neeltje Steeghs, Melinda Pruis, Carla van Herpen, Vickie Lu, John Redman, Xiaofei Zhou
Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions
Zhengzhi Liu, Zhongnan Xu, Zhenyue Gao, Qing Ren, Tianying Chang, Jinling Xue, Haimiao Yang
An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
Jayanthi Vijayakumar, Tufia Haddad, Kalpna Gupta, Janet Sauers, Douglas Yee
A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Yuji Morine, Kazuo Watanabe, Makoto Ueno, Tatsuya Ioka, Masashi Kanai, Shunsuke Kondo, Naohiro Okano, Kazuhiko Koike
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
Helei Hou, Yongjie Wang, Dantong Sun, Jingjuan Zhu, Man Jiang, Xuchen Zhang, Na Zhou, Chuantao Zhang, Tianjun Li, Xiaochun Zhang
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendás, Qi Xia, Ravit Geva, Emiliano Calvo
DGG-300273, a novel WNT/β-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells
Do Yeon Kim, Yea Seong Ryu, Eun-Sil Lee, Dong-In Koh, Jai-Hee Moon, Soo-A Jung, Mi Jin Kim, Hyeseon Yun, Ji-Eun You, Hong-Rae Jeong, Dong-Il Yoon, Chul Hee Kim, Seung-Woo Hong, Young-Dae Gong, Dong-Hoon Jin
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells
Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells
Alexander M. Scherbakov, Svetlana K. Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanovic, Olga E. Andreeva, Fedor B. Bogdanov, Diana I. Salnikova, Vladimir Jurisic, Igor V. Zavarzin, Valerii Z. Shirinian
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides
Alexander S. Vedenkin, Sergey V. Stovbun, Alexander A Bukhvostov, Dmitry V. Zlenko, Ivan S. Stovbun, Vladimir N. Silnikov, Valentin V. Fursov, Dmitry A. Kuznetsov
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma
Fumihiko Kinoshita, Yuka Oku, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Fumihiro Shoji, Tatsuro Okamoto
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
Shigemasa Takamizawa, Yuki Katsuya, Yi-Ning Chen, Takaaki Mizuno, Takafumi Koyama, Kazuki Sudo, Tatsuya Yoshida, Shunsuke Kondo, Satoru Iwasa, Kan Yonemori, Toshio Shimizu, Noboru Yamamoto, Shigenobu Suzuki
Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
Peng Yuan, Jinhua Song, Fei Wang, Guangyu Zhu, Baoan Chen